The Impact of Statin Dose, Class, and Intensity on Sepsis Mortality in Type 2 Diabetes Patients

Abstract

Abstract Aims: The study aims to investigate the impact of statin use on sepsis mortality in patients with type 2 diabetes (T2DM) in a dose-, class-, and use intensity-dependent manner. Methods: A retrospective cohort of 850,326 T2DM patients was analyzed using an inverse probability treatment-weighted Cox hazard model, with statin use status as a time-dependent variable. Results: Results showed that statin use was associated with a significant reduction in sepsis mortality risk (aHR=0.29) compared to non-users. Pitavastatin, rosuvastatin, pravastatin, atorvastatin, simvastatin, fluvastatin, and lovastatin were all associated with a lower sepsis mortality risk. Higher cumulative defined daily dose per year of statins was also associated with a lower sepsis mortality, with an optimal daily dose of 0.86 defined daily doses. Conclusion: These findings suggest that statin use may reduce sepsis mortality in T2DM patients and that higher doses are associated with greater protection.